In a report released today, Jay Olson from Oppenheimer assigned a Hold rating to ACADIA Pharmaceuticals (ACAD – Research Report), with a price target of $42.00. The company’s shares closed last Wednesday at $42.87. According to TipRanks.com, Olson has currently